AID Logo

Directory >> Nancy Kiviat, MD


Contact Information

Nancy Kiviat, MD

  • Professor, Department of Pathology
  • University of Washington

Dr. Kiviat's research focuses on studies of HIV-1, HIV-2, and HPV related cancers, as well as breast cancer, especially in Africa. In addition, she directs projects examining issues related to cervical cancer control both in developing countries and in the U.S. and studies exploring management of women with abnormal pap smears in this country. She directs several studies examining risk factors for HIV-1 and HIV-2 genital tract shedding in women and men. In addition, over the last seven years Dr. Kiviat has been involved in several projects examining the development of biomarkers for detection of cervical, heart, and ovarian cancer. Currently there are ongoing NIH-funded projects in Seattle and Senegal, West Africa. In both African and Seattle, her research groups are examining the relationship between HIV, specific types of HPV, immunosuppression, and risk of cervical and anal cancer.

In West Africa, in collaboration with Dr. Julie McElrath's lab at Fred Hutchinson Cancer Research Center, the Kiviat group is using ELISPOT assays to describe and contrast the immune response to HIV-1 and HIV-2 in order to understand why humans are able to control HIV-2 but not HIV-1. They have also been following prostitutes and non-prostitutes to examine the relationship between HIV-1, HIV-2, specific HPV types, and specific HPV 16 variants, immuno-suppression, and development of neoplasia. The group recently received funding for a study that will be done in conjunction with Dr. McDougall at the Fred Hutchinson Cancer Research Center that will examine the molecular characteristics of cancers arising in women with and without HIV infection.

Other ongoing projects in Senegal include a study examining and contrasting factors associated with genital tract virus shedding among those with HIV 1 and HIV 2. The Kiviat group has several studies examining new approaches to screening for cervical cancer and management of women with ASCUS and LGSIL. Various screening approaches are being examined, including the use of new assays for HPV DNA and recently developed technologies for improving cytology-based cervical cancer control. They have recently started several studies in which they are using microarrays to identify markers for detection and treatment of cervical and breast cancer. Dr. Kiviat collaborates with Drs. Koutsky, McElrath, and Mullins.

Selected Publications

Mao C, Balasubramanian A, Yu M, Kiviat N, et al. Evaluation of a new p16(INK4A) ELISA test and a high-risk HPV DNA test for cervical cancer screening: results from proof-of-concept study. Int J Cancer. 2007; 120(11): 2435-8.
PubMed Abstract

Xi LF, Koutsky LA, Hildesheim A, Galloway DA, Wheeler CM, Winer RL, Ho J, Kiviat NB. Risk for high-grade cervical intraepithelial neoplasia associated with variants of human papillomavirus types 16 and 18. Cancer Epidemiol Biomarkers Prev. 2007; 16(1): 4-10.
PubMed Abstract

Strauss R, Huser A, Ni S, Tuve S, Kiviat N, et al. Baculovirus-based vaccination vectors allow for efficient induction of immune responses against plasmodium falciparum circumsporozoite protein. Mol Ther. 2007; 15(1): 193-202.
PubMed Abstract

Feng Q, Hawes SE, Stern JE, Dem A, Sow PS, Dembele B, Toure P, Sova P, Laird PW, Kiviat NB. Promoter hypermethylation of tumor suppressor genes in urine from patients with cervical neoplasia. Cancer Epidemiol Biomarkers Prev. 2007; 16(6): 1178-84.
PubMed Abstract

to top